Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Liberty Global Ltd Class C (LBTYK) Price & Performance

Heron Therapeutics IncTrade
Liberty Global Ltd Class CTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Liberty Global Ltd Class C — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Liberty Global Ltd Class C trades at $10 (market cap $3.47B). The key difference: Liberty Global Ltd Class C is far larger — about 37.9× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.

HRTXLBTYK
Market Cap
$91.46M$3.47B
Sector
HealthTechnology
52-Week High
$1.96$12.67
52-Week Low
$0.39$10.00
Enterprise Value
$189.36M$10.75B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Liberty Global Ltd Class C

LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.

The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Liberty Global Ltd Class C

Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.

Read more on LBTYK